Statements (72)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
None reported
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:businessModel |
Strategic initiatives
Biopharmaceutical development |
| gptkbp:CEO |
gptkb:Dr._David_A._H._Hwang
|
| gptkbp:clinicalTrials |
Ongoing
Innovative approaches Diverse demographics Targeted therapies Published findings Multiple phases conducted Multiple sites globally Phase 1, 2, and 3 trials Phase 3 ongoing Positive results reported Published results |
| gptkbp:collaborations |
Academic institutions
|
| gptkbp:community |
Significant contributions
|
| gptkbp:communityEngagement |
Health awareness programs
|
| gptkbp:communityPartnerships |
Local health organizations
|
| gptkbp:employees |
Over 100
|
| gptkbp:financialPerformance |
Volatile
Growing revenue |
| gptkbp:financials |
Quarterly and annual reports
From investors |
| gptkbp:focus |
Cancer treatment
|
| gptkbp:founded |
2002
|
| gptkbp:founder |
gptkb:Dr._David_A._H._Hwang
|
| gptkbp:futurePlans |
New drug development
|
| gptkbp:hasCapacity |
Programs available
|
| gptkbp:hasMember |
Diverse expertise
|
| gptkbp:hasResearchInterest |
Ongoing analysis
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| gptkbp:healthcare |
Engagement efforts
|
| https://www.w3.org/2000/01/rdf-schema#label |
ATNX
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:investmentFocus |
Annual meetings
Venture capital funding Institutional and retail investors Dedicated team |
| gptkbp:leads |
ATNX-101
|
| gptkbp:market |
gptkb:North_America
Approximately $1 billion Scheduled for next year International markets Biotech_growth |
| gptkbp:marketSegment |
Global outreach
|
| gptkbp:partnerships |
Various pharmaceutical companies
Open for collaborations |
| gptkbp:patentCitation |
Multiple patents granted
|
| gptkbp:products |
Therapeutics
|
| gptkbp:regulatoryCompliance |
FDA_approved_drugs
FDA_and_EMA |
| gptkbp:research |
Grants and partnerships
|
| gptkbp:research_areas |
Hematology
|
| gptkbp:researchAreas |
Oncology
|
| gptkbp:researchInterest |
Research articles
Cutting-edge technologies With leading universities Secured funding |
| gptkbp:revenue |
Varies annually
|
| gptkbp:scientificName |
Renowned experts
|
| gptkbp:socialMedia |
Active presence
|
| gptkbp:stockSymbol |
gptkb:ATNX
|
| gptkbp:strategicGoals |
Expand product pipeline
|
| gptkbp:sustainabilityInitiatives |
Environmental responsibility
|
| gptkbp:technology |
Innovative drug delivery
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
Multiple drug candidates
|
| gptkbp:updates |
Regular communications
|
| gptkbp:website |
www.atnxbio.com
|